Previous Blogs

Avatar

By Lynn Yao

December 28, 2020

A parenteral drug product contaminated by particles is a potential health threat. In the bloodstream, particles can cause serious issues, such as capillary occlusion and immunogenic responses. In most cases, the observation of particles in a drug product leads to a recall.

Avatar

By Page McAndrew, PhD

September 04, 2020

Gene therapies are stored and shipped at ultra-low temperature (approximately -80oC, either in a refrigerator or on dry ice). This provides a challenge to the primary package systems in maintaining container closure integrity (CCI), especially systems comprising glass vials and elastomer stoppers. These materials have different coefficients of thermal expansion. Upon cooling from room temperature to ultra-low temperature, they contract at different rates; this may lead to gaps and CCI loss.

Avatar

By Olga Laskina, Ph.D.

July 10, 2020

The overall quality of a final drug product depends on the components of its packaging and delivery systems.  The use of visually inspected components reduces the risk of defective components and helps ensure patient safety.

Avatar

By Page McAndrew PhD.

May 22, 2020

Developing a SARS-CoV-2 vaccine presents numerous and unprecedented challenges; prominent among them are greatly accelerated timelines. Ordinarily for a new drug product, there is sufficient time for selection/evaluation of the vial/stopper packaging system – one that guarantees quality and safety from manufacture through delivery. This is not the case for a SARS-CoV-2 vaccine where the primary packaging system must be chosen quickly, creating a higher risk.

Avatar

By Jessie Zhang

January 28, 2020

The Packaging Academy has been organized by West in Asia Pacific for the past 5 years, beginning in 2015, and serves as a valued training platform for our customers in injectable packaging both in the areas of containment and delivery systems.

Avatar

By Bjoern Henze, Ph.D.

January 10, 2020

Containment/delivery systems for sensitive biologic drugs must provide the chemical, physical, and performance properties required to ensure product quality through shelf life. Further, they must be compatible with fill/finish operations, and enable functional performance during administration. Legacy rubber components may no longer meet the increasing technical and regulatory requirements of current and future biologic drug products.